September 15, 2026 · Phase 2 readout
ZURA Phase 2 readout: a negative outcome, -5.4%
On September 15, 2026, Tibulizumab Dose A — Zura Bio Ltd (Hidradenitis Suppurativa (HS)) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -5.4% in the window around the event. It had already run -6.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$5.21
1d before
$4.93
Event day
$4.93
1d after
$4.93
5d after
Our prediction vs. the result
CatalystAlert called this one up (+2.6% expected); the stock actually moved -5.4%. Model confidence at the time: 40%.
See the full scored track recordPre-catalyst setup
-6.5%
30-day run-up
5867%
30-day volatility
0.7×
volume spike